VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Viking Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$25.05−0.12 (-0.48%)

Close on Oct 19, 2026

Market cap: $2.91B
P/E (TTM): –
Dividend yield: –

Viking Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31	Q4 2019 2019-12-31	Q3 2019 2019-09-30	Q2 2019 2019-06-30	Q1 2019 2019-03-31	Q4 2018 2018-12-31	Q3 2018 2018-09-30	Q2 2018 2018-06-30	Q1 2018 2018-03-31	Q4 2017 2017-12-31	Q3 2017 2017-09-30	Q2 2017 2017-06-30	Q1 2017 2017-03-31	Q4 2016 2016-12-31	Q3 2016 2016-09-30
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Research & Development	116	150	153	90	60	41	31	23	24	24	21	18	14	11	16	12	14	13	9.85	11	13	12	9.05	7.12	7.78	7.99	6.45	5.28	7.33	4.50	5.09	5.69	5.22	3.04	3.03	3.47	3.72	3.53	2.65	2.10
General & Administrative	17	14	11	8.61	14	14	15	14	10	9.97	8.78	8.89	9.82	9.53	4.11	4.24	4.09	3.69	2.66	2.61	2.74	2.69	2.22	2.73	2.83	2.96	2.42	2.16	2.24	2.31	1.95	1.71	1.70	1.76	1.39	1.23	1.27	1.44	1.09	1.16
Operating Expenses	133	164	165	99	75	55	46	37	34	34	29	27	24	21	20	16	18	16	13	13	16	14	11	9.84	11	11	8.87	7.44	9.57	6.81	7.04	7.39	6.93	4.81	4.43	4.69	4.98	4.97	3.74	3.26
Operating Income	-133	-164	-165	-99	-75	-55	-46	-37	-34	-34	-29	-27	-24	-21	-20	-16	-18	-16	-13	-13	-16	-14	-11	-9.84	-11	-11	-8.87	-7.44	-9.57	-6.81	-7.04	-7.39	-6.93	-4.81	-4.43	-4.69	-4.98	-4.97	-3.74	-3.26
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.02	–	–	–	–	–	–
Other Non-Operating Income	4.58	5.80	7.08	7.77	9.01	9.84	11	12	12	6.72	4.68	4.73	4.52	1.01	0.72	0.42	0.20	0.14	0.15	0.16	0.16	0.22	0.32	0.56	1.03	1.26	1.42	1.71	1.90	1.88	1.80	0.79	0.25	1.25	0.34	-1.41	-0.19	-0.25	0.09	-0.54
Net Income incl. Noncontrolling Interests	-128	-158	-158	-91	-66	-46	-35	-25	-22	-27	-25	-23	-19	-20	-20	-16	-17	-16	-12	-13	-15	-14	-11	-9.29	-9.57	-9.69	-7.45	-5.73	-7.67	-4.92	-5.24	-6.60	-6.67	-3.55	-4.09	-6.10	–	–	–	–
Net Income	-128	-158	-158	-91	-66	-46	-35	-25	-22	-27	-25	-23	-19	-20	-20	-16	-17	-16	-12	-13	-15	-14	-11	-9.29	-9.57	-9.69	-7.45	-5.73	-7.67	-4.92	-5.24	-6.60	-6.67	-3.55	-4.09	-6.10	-5.17	-5.22	-3.64	-3.81
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-4.92	–	–	–	-3.55	–	–	–	-5.22	–	–
EPS (Basic)(per share)	-1.10	-1.37	-1.38	-0.81	-0.58	-0.41	-0.32	-0.22	-0.20	-0.26	-0.25	-0.23	-0.19	-0.25	-0.26	-0.21	-0.23	-0.21	-0.16	-0.17	-0.20	-0.19	-0.15	-0.13	-0.13	-0.13	-0.10	-0.08	-0.11	-0.07	-0.07	-0.11	-0.13	-0.08	-0.14	-0.22	-0.21	-0.23	-0.18	-0.20
EPS (Diluted)(per share)	-1.10	-1.37	-1.38	-0.81	-0.58	-0.41	-0.32	-0.22	-0.20	-0.26	-0.25	-0.23	-0.19	-0.25	-0.26	-0.21	-0.23	-0.21	-0.16	-0.17	-0.20	-0.19	-0.15	-0.13	-0.13	-0.13	-0.10	-0.08	-0.11	-0.07	-0.07	-0.11	-0.13	-0.10	-0.14	-0.22	-0.21	-0.23	-0.18	-0.20
Shares Outstanding (Basic, Weighted)(shares)	116	116	114	112	112	112	111	111	110	103	100	100	99	78	77	77	77	77	78	78	78	75	73	73	72	72	72	72	72	72	71	61	53	45	30	27	24	22	20	19
Shares Outstanding (Diluted, Weighted)(shares)	116	116	114	112	112	112	111	111	110	103	100	100	99	78	77	77	77	77	78	78	78	75	73	73	72	72	72	72	72	72	71	61	53	45	30	27	24	22	20	19

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -47.3%

Financial strength

Current ratio: 4.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 114.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 7.13
Dividend yield: –